Results 11 to 20 of about 929,917 (139)

Iatrogenic osteomalacia caused by intravenous administration of saccharated ferric oxide [PDF]

American Journal of Hematology, 1993
Shoichiro Irimajiri, Yasuo Matsuoka
exaly   +3 more sources

Correction to: Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study. [PDF]

Int J Hematol, 2022
Kawabata H, Tamura T, Tamai S, Fujibayashi A, Sugimura M, Study Group.   +5 more
europepmc   +2 more sources

Role of free hydrochloric acid in the low-cost regeneration of ferric chloride etchant by oxygen gas [PDF]

, 2005
This thesis concerns the development of a low cost and environment- friendly method for the regeneration of the most widely used aqueous etchant, ferric chloride, found in photochemical machining (PCM) facilities.
Jefferies, P. J.
core   +7 more sources

Removal and recovery of phosphorus from municipal wastewaters using a ferric nanoparticle adsorbent [PDF]

, 2010
Phosphorus is removed from wastewater streams to prevent the ecologically harmful effects of eutrophication in receiving natural systems. Current chemical and biological techniques for removing phosphorus from wastewater are not able to practicably ...
Martin, Benjamin D.
core   +7 more sources

Ferric derisomaltose for the treatment of iron deficiency anemia with postpartum hemorrhage: Results of a single‐arm, open‐label, phase 3 study in Japan

Journal of Obstetrics and Gynaecology Research, Volume 49, Issue 3, Page 946-955, March 2023., 2023
Abstract Aim Single‐arm, open‐label, phase 3 study to evaluate the efficacy and safety of ferric derisomaltose (FDI) for iron deficiency anemia (IDA) in Japanese women with postpartum hemorrhage (PPH). Methods Postpartum women aged 20–39 years with serum ferritin <25.0 ng/ml, hemoglobin (Hb) <10.0 g/dl, and blood loss ≥500 ml within 24 h post‐delivery ...
Motoi Sugimura, Yasuyoshi Ohtani, Soichiro Tamai, Umi Kishimoto, Naoki Ito   +4 more
wiley   +1 more source

Global guidance for the recognition, diagnosis, and management of tumor‐induced osteomalacia

Journal of Internal Medicine, Volume 293, Issue 3, Page 309-328, March 2023., 2023
Abstract Tumor‐induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by mesenchymal tumors that secrete fibroblast growth factor 23 (FGF23). Patients present with progressive bone pain, muscle weakness, and fragility fractures. TIO is characterized by hypophosphatemia, excess renal phosphate excretion, and low/inappropriately normal 1,25 ...
Suzanne M. Jan de Beur, Salvatore Minisola, Wei‐bo Xia, Bo Abrahamsen, Jean‐Jacques Body, Maria Luisa Brandi, Roderick Clifton‐Bligh, Michael Collins, Pablo Florenzano, Pascal Houillier, Yasuo Imanishi, Erik A. Imel, Aliya A. Khan, M. Carola Zillikens, Seiji Fukumoto   +14 more
wiley   +1 more source

Systematic review and meta‐analysis of intravenous iron‐carbohydrate complexes in HFrEF patients with iron deficiency

ESC Heart Failure, Volume 10, Issue 1, Page 44-56, February 2023., 2023
Abstract Iron deficiency (ID) is a common co‐morbidity in patients with heart failure (HF). The present meta‐analysis evaluates the effect of intravenous (IV) iron‐carbohydrate complex supplementation in patients with HF with reduced ejection fraction (HFrEF) and ID/iron deficiency anaemia (IDA).
Andrew Sindone, Wolfram Doehner, Josep Comin‐Colet   +2 more
wiley   +1 more source

Osteomalacia as a Complication of Intravenous Iron Infusion: A Systematic Review of Case Reports

Journal of Bone and Mineral Research, Volume 37, Issue 6, Page 1188-1199, June 2022., 2022
ABSTRACT Randomized control trials (RCTs) have shown that certain intravenous iron preparations can induce high levels of fibroblast growth factor 23 (FGF‐23) and persistent hypophosphatemia. Repeated iron infusions may lead to prolonged hypophosphatemia and osteomalacia events not captured by RCTs. Several previous case reports have described skeletal
Tatiane Vilaca, Nalini Velmurugan, Christopher Smith, Bo Abrahamsen, Richard Eastell   +4 more
wiley   +1 more source

Severe Hypophosphatemia Occurring After Repeated Exposure to a Parenteral Iron Formulation

Case Reports in Endocrinology, Volume 2022, Issue 1, 2022., 2022
Hypophosphatemia is a less known complication of parenteral iron use, particularly after the use of certain iron formulations. We report the case of a young male with inflammatory bowel disease and iron deficiency anemia, who developed severe symptomatic hypophosphatemia after his third exposure to iron carboxymaltose with no evidence of the same ...
Keerthana Haridas, Alice Yau, Toshihiro Kita   +2 more
wiley   +1 more source

Safety of iron hydroxide adipate tartrate as a novel food pursuant to Regulation (EU) 2015/2283 and as a source of iron in the context of Directive 2002/46/EC

EFSA Journal, Volume 19, Issue 12, December 2021., 2021
Abstract Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on iron hydroxide adipate tartrate as a novel food (NF) pursuant to Regulation (EU) 2015/2283 and as a source of iron in the context of Directive 2002/46/EC.
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Dominique Turck, Torsten Bohn, Jacqueline Castenmiller, Stefaan De Henauw, Karen Ildico Hirsch‐Ernst, Alexandre Maciuk, Inge Mangelsdorf, Harry J McArdle, Androniki Naska, Carmen Pelaez, Kristina Pentieva, Alfonso Siani, Frank Thies, Sophia Tsabouri, Marco Vinceti, Francesco Cubadda, Thomas Frenzel, Marina Heinonen, Miguel Prieto Maradona, Rosangela Marchelli, Monika Neuhäuser‐Berthold, Morten Poulsen, Josef Rudolf Schlatter, Henk van Loveren, Andrea Germini, Helle Katrine Knutsen   +27 more
wiley   +1 more source